

Human Retroviral Infections

Immunological and
Therapeutic Control

INFECTIOUS AGENTS AND PATHOGENESIS

Series Editors: Mauro Bendinelli, *University of Pisa*
Herman Friedman, *University of South Florida*
College of Medicine

Recent volumes in this series:

DNA TUMOR VIRUSES

Oncogenic Mechanisms

Edited by Guiseppe Barbanti-Brodano, Mauro Bendinelli,
and Herman Friedman

ENTERIC INFECTIONS AND IMMUNITY

Edited by Lois J. Paradise, Mauro Bendinelli, and Herman Friedman

FUNGAL INFECTIONS AND IMMUNE RESPONSES

Edited by Juneann W. Murphy, Herman Friedman,
and Mauro Bendinelli

HERPESVIRUSES AND IMMUNITY

Edited by Peter G. Medveczky, Herman Friedman,
and Mauro Bendinelli

HUMAN RETROVIRAL INFECTIONS

Immunological and Therapeutic Control

Edited by Kenneth E. Ugen, Mauro Bendinelli,
and Herman Friedman

MICROORGANISMS AND AUTOIMMUNE DISEASES

Edited by Herman Friedman, Noel R. Rose, and Mauro Bendinelli

OPPORTUNISTIC INTRACELLULAR BACTERIA AND IMMUNITY

Edited by Lois J. Paradise, Herman Friedman, and Mauro Bendinelli

PSEUDOMONAS AERUGINOSA AS AN OPPORTUNISTIC PATHOGEN

Edited by Mario Campa, Mauro Bendinelli, and Herman Friedman

PULMONARY INFECTIONS AND IMMUNITY

Edited by Herman Chmel, Mauro Bendinelli, and Herman Friedman

RAPID DETECTION OF INFECTIOUS AGENTS

Edited by Steven Specter, Mauro Bendinelli, and Herman Friedman

RICKETTSIAL INFECTION AND IMMUNITY

Edited by Burt Anderson, Herman Friedman, and Mauro Bendinelli

A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact the publisher.

Human Retroviral Infections

Immunological and
Therapeutic Control

Edited by

Kenneth E. Ugen

*University of South Florida College of Medicine
Tampa, Florida*

Mauro Bendinelli

*University of Pisa
Pisa, Italy*

and

Herman Friedman

*University of South Florida College of Medicine
Tampa, Florida*

Kluwer Academic Publishers

New York, Boston, Dordrecht, London, Moscow

eBook ISBN: 0-306-46819-0
Print ISBN: 0-306-46222-2

©2002 Kluwer Academic Publishers
New York, Boston, Dordrecht, London, Moscow

All rights reserved

No part of this eBook may be reproduced or transmitted in any form or by any means, electronic, mechanical, recording, or otherwise, without written consent from the Publisher

Created in the United States of America

Visit Kluwer Online at: <http://www.kluweronline.com>
and Kluwer's eBookstore at: <http://www.ebooks.kluweronline.com>

Contributors

- MICHAEL G. AGADJANYAN • Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, and Institute of Viral Preparations, Russian Academy of Medical Science, Moscow, Russia 129028
- J. ARP • Gene Therapy and Molecular Virology Group, The John P. Robarts Research Institute, and the Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada, N6A 5K8
- VELPANDI AYYAVOO • Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261
- MOSI K. BENNETT • Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
- EWA BJÖRLING • Microbiology and Tumorbiology Center, Karolinska Institute, S-171 77 Stockholm, Sweden
- JEAN D. BOYER • Stellar-Chance Laboratories, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 191046100
- CYNTHIA L. BRISTOW • McLendon Clinical Laboratories, Department of Pathology and Laboratory Medicine, University of North Carolina Hospitals, Chapel Hill, North Carolina 27514
- GEORGE J. CIANCIOLO • Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710
- JOSEPH P. COTROPIA • BioClonetics, Inc., Philadelphia, Pennsylvania 19147, and Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

G. A. DEKABAN • Gene Therapy and Molecular Virology Group, The John P. Robarts Research Institute, and the Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada, N6A 5K8

MAITE DE LA MORENA • Washington University School of Medicine, St. Louis, Missouri 63110

ROBERT W. DOMS • Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104

BENJAMIN J. DORANZ • Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104

RALPH DORNBURG • The Dorrance H. Hamilton Laboratories, Center for Human Virology, Division of Infectious Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107

PATRICIA J. EMMANUEL • Department of Pediatrics, College of Medicine, University of South Florida, Tampa, Florida 33612

G. FRANCHINI • Basic Research Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892

TERESA C. GENTILE • Department of Medicine, SUNY Health Sciences Center, Syracuse, New York 13210

MAUREEN M. GOODENOW • Department of Pathology, Immunology, and Laboratory Medicine, and Division of Immunology and Infectious Diseases, Department of Pediatrics, College of Medicine, Health Science Center, University of Florida, Gainesville, Florida 32610

THOMAS KIEBER-EMMONS • Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 191046082

SAGAR KUDCHODKAR • Stellar-Chance Laboratories, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104

THOMAS P. LOUGHRAN • Program Leader, Hematological Malignancies, H. Lee Moffitt Cancer Center and Research Institute, Veterans Administration Hospital, and Departments of Medicine and Microbiology/Immunology, University of South Florida College of Medicine, Tampa, Florida 33612

JERRY R. MCGHEE • Department of Microbiology, Immunobiology Vac-

- cine Center, University of Alabama at Birmingham, Birmingham, Alabama 35294
- T. NAGASHUNMUGAM • Stellar-Chance Laboratories, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104
- ROBERT P. NELSON, JR. • Indiana University School of Medicine, Indianapolis, Indiana 46202
- ELENA E. PEREZ • Department of Pathology, Immunology, and Laboratory Medicine, and Medical Scientist Training Program, College of Medicine, Health Science Center, University of Florida, Gainesville, Florida 32610
- A. PETERS • Gene Therapy and Molecular Virology Group, The John P. Robarts Research Institute, and the Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada, N6A 5K8
- ROGER POMERANTZ • The Dorrance H. Hamilton Laboratories, Center for Human Virology, Division of Infectious Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107
- AMI R. SHAH • Rollins School of Public Health, Emory University, Atlanta, Georgia 30322
- JOHN W. SLEASMAN • Department of Pathology, Immunology, and Laboratory Medicine, and Division of Immunology and Infectious Diseases, Department of Pediatrics, College of Medicine, Health Science Center, University of Florida, Gainesville, Florida 32610
- HERMAN F. STAATS • Departments of Medicine and Immunology, Center for AIDS Research, Duke University Medical Center, Durham, North Carolina 27710
- KENNETH E. UGEN • Department of Medical Microbiology and Immunology, University of South Florida College of Medicine, Tampa, Florida 33612
- DAVID B. WEINER • Stellar-Chance Laboratories, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 191046100

Preface to the Series

The mechanisms of disease production by infectious agents are presently the focus of an unprecedented flowering of studies. The field has undoubtedly received impetus from the considerable advances recently made in the understanding of the structure, biochemistry, and biology of viruses, bacteria, fungi, and other parasites. Another contributing factor is our improved knowledge of immune responses and other adaptive or constitutive mechanisms by which hosts react to infection. Furthermore, recombinant DNA technology, monoclonal antibodies, and other, newer methodologies have provided the technical tools for examining questions previously considered too complex to be successfully tackled. The most important incentive of all is probably the regenerated idea that infection might be the initiating event in many clinical entities presently classified as idiopathic or of uncertain origin.

Infectious pathogenesis research holds great promise. As more information is uncovered, it is becoming increasingly apparent that our present knowledge of the pathogenic potential of infectious agents is often limited to the most noticeable effects, which sometimes represent only the tip of the iceberg. For example, it is now well appreciated that pathologic processes caused by infectious agents may emerge clinically after an incubation of decades and may result from genetic, immunologic, and other indirect routes more than from the infecting agent in itself. Thus, there is a general expectation that continued investigation will lead to the isolation of new agents of infection, the identification of hitherto unsuspected etiologic correlations, and, eventually, more effective approaches to prevention and therapy.

Studies on the mechanisms of disease caused by infectious agents demand a breadth of understanding across many specialized areas, as well as

much cooperation between clinicians and experimentalists. The series *Infectious Agents and Pathogenesis* is intended not only to document the state of the art in this fascinating and challenging field, but also to help lay bridges among diverse areas and people.

M. Bendinelli

H. Friedman

Preface

The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquired immunodeficiency syndrome (AIDS) epidemic began, and it was demonstrated that a retrovirus, originally designated the human T cell lymphotropic virus type 3, was the causal agent of this syndrome. This virus, later named the human immunodeficiency virus type 1 (HIV-1), has since been extensively studied in terms of its pathogenesis as well as its ability to elicit immune responses. In that time, a tremendous amount of information has been obtained about the virus. Although recent drug regimens have been useful in significantly lowering viral loads and perhaps maintaining an asymptomatic state among individuals infected with HIV-1, an established “cure” for AIDS eludes us. In addition, the effective drug therapies are very expensive, and are not available to infected people in the third world, where greater than 90% of new infections occur. Furthermore, the development of viral resistance against the drug therapies is an additional concern.

Despite extensive study, no effective vaccine has been developed. One of the problems in developing an effective vaccine against HIV-1 is the ability of the virus, particularly in the immunogenic envelop glycoprotein, to undergo amino acid hypervariability. Therefore, vaccines generated against one envelop glycoprotein are ineffective against other viruses with more hypervariable envelopes.

Although the rate of new HIV-1 infections in the United States has slowed and appears to have reached a plateau, nearly 16,000 people per day worldwide become newly infected with this devastating virus. Ominously, it is predicted that at the turn of the century, over 40 million people across the globe will be infected. Clearly, the development of new effective drug therapies, as well as immune prophylactic and therapeutic regimens against

HIV and AIDS is warranted. The chapters in this volume, written by experts in the field of human retroviral pathogenesis, vaccine development, and the clinical treatment of AIDS, summarize the current status of work in these areas as well as future directions for research and therapeutic development.

The first chapter, by Dr. Bristow, deals with the important descriptions of the two principal viremias of HIV-1, sexual (heterologous) transmission and autologous transmission of viruses between cells within the same host. This information is relevant for the development of methods to limit the spread of HIV-1 infection. Drs. Gentile and Loughran then describe evidence for the role of the human T cell leukemia viruses (HTLV) in the etiology and pathogenesis of disorders other than ATL. This is an interesting and important area because of evidence suggesting that the HTLVs may have a role in a number of autoimmune diseases. Next, Dr. Cianciolo discusses the evidence for the immunomodulatory and immunosuppressive activity for a number of HIV-1 proteins including gp120 and gp41 as well as the regulatory proteins Tat and Nef. Dr. Kieber-Emmons describes the importance of carbohydrate moieties and glycosylation patterns in HIV-1 and their role in masking potentially immunogenic and therapeutically important epitopes. Drs. Bennett and Agadjanyan summarize some of the immunologic and molecular aspects of HTLV-I and HTLV-II infection, emphasizing the role of adhesion molecules in the binding of these two viruses to infectible target cells.

The next set of chapters deals with issues concerning the development of immunologic interventions against HTLV, HIV-2, and HIV-1, including vaccine development and passive immunotherapies. Dr. Franchini and colleagues describe the current status of efforts to develop a vaccine against HTLV-I, a retrovirus that infects 10–20 million people worldwide. Dr. Björling discusses immune responses against HIV-2 and how these responses are important for the development of vaccine strategies against this retrovirus, which primarily infects individuals in West Africa. Drs. Staats and McGhee deal with the important need to develop vaccine strategies against HIV-1 which will protect against mucosal infection. Since HIV-1 is transmitted primarily by mucosal routes, this is a very timely and important issue in the area of HIV-1 vaccinology. In terms of novel vaccine strategies against HIV-1, Dr. Boyer and colleagues describe the nucleic acid (DNA) vaccination technology. This approach, which appears to mimic live, attenuated viral vaccines without major safety concerns, elicits both humoral and cytotoxic T cell responses against HIV-1, and is currently in several human clinical trials. Drs. Cotropia and Ugen describe the current status of passive immunotherapy and immunoprophylaxis against HIV-1, including the use of human polyclonal HIV immunoglobulins and specific neutralizing human monoclonal antibodies. The set of chapters dealing with immunologic interven-

tions ends with the description by Dr. Ayyavoo and colleagues of efforts to target the accessory genes of HIV-1 for vaccine development and immunotherapy.

The final set of chapters deals with developments in therapeutic interventions against HIV-1 infection and AIDS using drugs or gene therapy. Drs. Doranz and Doms discuss the role of chemokine receptors in mediating entry of HIV-1 into cells as well as the design of new antiviral therapeutics that may prevent HIV from using these receptors. Dr. Goodenow and colleagues then summarize the activities of the therapeutically important protease inhibitors and, in particular, describe the role of genetic variability of the HIV-1 protease in modulating the response to these drugs in pediatric patients. Drs. Dornburg and Pomerantz follow with a chapter that describes current ideas and implementations of gene therapeutic regimens against HIV-1, as well as future possibilities of such an approach. The volume concludes with a chapter by Dr. Nelson and colleagues on the current status of the clinical use of antiretroviral therapy against pediatric HIV, the relative effectiveness of this therapy, and the need for the development of new therapies.

It is anticipated by the editors as well as by the authors of the individual chapters that this volume will provide a useful summary of the current status of immunologic and therapeutic interventions against human retroviral infections, most notably HIV-1. It is hoped that the need is made apparent for the development of efficacious vaccines against both HIV-1 and HTLV-I, as well as for the development of novel drug therapies and regimens such as gene therapy against HIV-1. The editors thank Ilona Friedman for excellent editorial assistance in coordinating and assisting in the preparation of the manuscripts for this volume.

Kenneth E. Ugen
Mauro Bendinelli
Herman Friedman

Contents

1. The Two Principal Viremias of HIV: A Comparison of Viral and Host Characteristics 1

CYNTHIA L. BRISTOW

1. Introduction	1
2. Sexual Transmission	3
2.1. The Infectious Unit	3
2.2. The Target Cell	3
2.3. The Environment	4
3. Autologous Transmission	7
3.1. The Infectious Unit	7
3.2. The Target Cell	8
3.3. The Environment	9
4. Conclusions	11
References	11

2. Potential Role of Human T-cell Leukemia/Lymphoma Viruses (HTLV) in Diseases Other Than Acute T-cell Leukemia/Lymphoma (ATL) 17

TERESA C. GENTILE and THOMAS P. LOUGHRAN

1. Introduction	17
2. Neurologic Disease	18
3. Hematologic Disease	20
4. Autoimmune/Inflammatory	22
5. Dermatologic Disease	23

6. Other Reported Disease Associations	24
References	24
3. Viral-Related Proteins in Immune Dysfunction Associated with AIDS	29
GEORGE J. CIANCIOLO	
1. Immunologic Dysfunction Associated with HIV Infection	31
2. Reported Effects of HIV-1 Tat on Immune Cell Function	31
3. Reported Effects of HIV-1 gp120 on Immune Cell Function	35
4. Reported Effects of HIV-1 gp41 on Immune Cell Function	41
5. Reported Effects of HIV-1 Nef on Immune Cell Function	44
6. Summary	53
References	53
4. Carbohydrate Interactions and HIV-1	61
THOMAS KIEBER-EMMONS	
1. Introduction	61
2. Carbohydrate Structures Are Ubiquitous in Nature	63
3. Influence of Carbohydrate Moieties on the Immunogenicity of HIV	67
4. Role of Carbohydrate in Vaccine Strategies to HIV	72
5. Mucosal Immune Responses	78
6. Summary	79
References	80
5. HTLV-I and HTLV- II Infection: Immunological and Molecular Aspects	87
MOSI K. BENNETT and MICHAEL G. AGADJANYAN	
1. Introduction	87
2. Biology of HTLV	88
3. HTLV Vaccine Development	91
4. Receptors for HTLV	93
5. Adhesion Molecules and HTLV Infection	95
References	103

6. Vaccine Approaches for Human T-cell Lymphotropic Virus Type I 109

G. A. DEKABAN, A. PETERS, J. ARP, and G. FRANCHINI

1. Introduction	109
2. Issues Relevant to HTLV-I Vaccine Development	111
2.1. HTLV-I Tropism	111
2.2. The Natural Immune Response to HTLV-I Infection	112
2.3. Feasibility of Generating an HTLV-I Vaccine	112
2.4. Genetic Stability	112
3. Available Animal Models	113
3.1. Rodent Models	113
3.2. Nonhuman Primate Models	115
4. Modes of Challenge	116
5. Vaccine Approaches Relevant to HTLV-I	117
5.1. Inactivated and Live Attenuated Viruses	117
5.2. Subunit Approach	118
5.3. Live Vectors	118
5.4. Immunization by DNA Gene Transfer	119
6. HTLV-I Vaccine Candidates	120
6.1. Tax	121
6.2. Pol and pX Region Proteins	121
6.3. Envelope Glycoprotein	122
6.4. Gag	123
6.5. Polyvalent Vaccine	124
7. HTLV-I Animal Vaccine Challenge Studies	125
7.1. Rat Vaccine Studies	125
7.2. Rabbit Vaccine Studies	126
7.3. Nonhuman Primate Vaccine Studies	129
8. Summary	129
References	131

7. Immune Responses against HIV-2 143

EWA BJÖRLING

1. Introduction	143
2. Properties of Different HIV-2 Proteins	144
3. Immune Responses against HIV-2	144
3.1. Humoral Immunity	145
3.2. Antibody-Dependent Cellular Cytotoxicity	151

3.3. Cell-Mediated Immunity	153
4. Conclusion	156
References	157
8. HIV Mucosal Vaccines	165
HERMAN F. STAATS and JERRY R. MCGHEE	
1. Introduction	165
2. HIV Infection at Mucosal Surfaces	166
3. Correlates of Protection for Mucosally Transmitted HIV	168
3.1. HIV-Exposed but Uninfected	168
3.2. Mucosal SIV Challenge in Nonhuman Primates	170
4. Mucosal HIV Vaccine Needed	170
4.1. Organization of the Mucosal Immune System	171
4.2. Mucosal Antibody Responses: Secretory-IgA	172
4.3. Mucosal Cell-Mediated Immunity: Cytotoxic T Lymphocytes	174
4.4. Routes of Immunization for the Induction of Anti-HIV Mucosal Immune Responses	174
5. Mucosal HIV Vaccine Strategies	175
5.1. Protein Subunits	175
5.2. Peptide Vaccines	177
5.3. Virus-like Particles	178
5.4. Recombinant Viral Vectors	179
5.5. Recombinant Bacterial Vectors	179
5.6. DNA Vaccines	180
5.7. Live Attenuated SIV	180
6. Mucosal Adjuvants	181
7. Conclusions	181
References	182
9. Nucleic Acid Vaccination against HIV-1	191
AMI R. SHAH, DAVID B. WEINER, and JEAN D. BOYER	
1. Introduction	191
2. Obstacles to HIV-1 Vaccine Development	192
2.1. Introduction	192
2.2. Immune Responses to HIV-1 and Potential Correlates of Protection	194

3. The Genome of HIV-1 and Targets for Nucleic Acid Vaccination	196
4. DNA-Based Vaccines	199
5. Progress of Nucleic Acid Immunization against HIV-1	200
5.1. Murine Studies	200
5.2. Primate Studies	206
5.3. Human Studies	208
6. Conclusion	210
References	210
10. Passive Immunotherapy against HIV-1: Current Status and Potential	217
JOSEPH P. COTROPIA and KENNETH E. UGEN	
1. Introduction	217
2. Humoral Immune Responses against HIV-1	218
3. Humoral Immune Responses against gp120	219
4. Humoral Immune Responses against gp41	219
5. Convergent/Synergistic Passive Immunotherapy	222
6. Evidence for Protective Efficacy of Humoral Immunity against HIV-1	223
7. Passive Immunotherapy Trials of Clinical Relevance Utilizing HIV Immune Serum Globulin	224
8. Monoclonal Antibodies Utilized in Passive Immunotherapy	225
8.1. Chimpanzee Model	225
8.2. Human Trials	227
8.3. hu-PBL-SCID Mouse Model	229
9. Summary	230
References	232
11. Human Immunodeficiency Virus Type 1 Accessory Genes: Targets for Therapy	239
SAGAR KUDCHODKAR, T. NAGASHUNMUGAM, and VELPANDI AYYAVOO	
1. Introduction	239
2. Vif	242
2.1. Structure and Function	242
2.2. Vaccine and Drug Studies	245

3. Vpu	247
3.1. Structure and Function	247
3.2. Vaccine and Drug Studies	249
4. Nef	250
4.1. Structure and Function	250
4.2. Vaccine and Drug Studies	252
5. Vpr	253
5.1. Structure and Function	253
5.2. Vaccine and Drug Studies	255
6. Conclusion	257
References	257
12. A New Generation of Antiviral Therapeutics Designed to Prevent the Use of Chemokine Receptors for Entry by HIV-1 . . .	269
BENJAMIN J. DORANZ and ROBERT W. DOMS	
1. Introduction	269
2. Chemokine Receptors as HIV-1 Coreceptors	270
3. Chemokine Receptors as Pathogenic Determinants	272
4. Chemokine Inhibition of HIV-1	273
5. Therapeutics Directed at Chemokine Receptors	274
6. Small-Molecule Inhibitors of Chemokine Receptors	276
7. Future Directions	279
References	279
13. Protease Inhibitors and HIV-1 Genetic Variability in Infected Children	287
MAUREEN M. GOODENOW, ELENA E. PEREZ, and JOHN W. SLEASMAN	
1. Antiviral Drug Therapies	287
1.1. Introduction	287
1.2. HIV-1 Targets for Drugs	288
1.3. HIV-1 Protease	288
1.4. Viral Drug Resistance	289
2. Antiviral Drugs and Pediatric Patients	291
2.1. Drugs for HIV-1-Infected Children	291
2.2. Protease Inhibitors and Clinical Response	292

2.3. Immune Reconstitution Following PR Inhibitor Therapy in Children	294
3. Genetic Analysis of Protease in Response to Protease Inhibitors	295
3.1. Patients	295
3.2. Methods	295
3.3. Phylogenetic Trees	296
3.4. Genotypic Resistance in Protease	297
3.5. Genetic Distance in Protease over Time	298
3.6. Models for Evolution of Virus with Inhibitor	298
4. Virus from Other Perspectives	300
4.1. Variability in env Region of the Virus Genome	300
4.2. Genetic Analysis and Reservoirs of Viruses	303
References	303
14. Gene Therapy and HIV-1 Infection: Experimental Approaches, Shortcomings, and Possible Solutions	307
RALPH DORNBURG and ROGER POMERANTZ	
1. HIV-1 Infection and Conventional Pharmaceutical Agents	307
2. Antisense RNAs and Ribozymes	308
3. RNA Decoys	310
4. Transdominant Mutant Proteins	310
5. Toxic Genes	311
6. CD4 as Decoy	312
7. Single-Chain Antibodies	312
8. Gene Delivery of Antiviral Agents	312
9. Other New Potential Vector Systems	316
10. Other Potential Problems	317
References	318
15. Pediatric HIV: Antiretroviral Therapy	325
ROBERT P. NELSON, JR., PATRICIA J. EMMANUEL, and MAITE DE LA MORENA	
1. Introduction	325
2. Antiretroviral Agents	331
2.1. Nucleoside Analogue Reverse Transcriptase Inhibitors	331

2.2. Nonnucleoside Reverse Transcriptase Inhibitors	334
2.3. Protease Inhibitors	335
2.4. Nucleotide Reverse Transcriptase Inhibitor	337
3. Pediatric Antiretroviral Treatment	337
3.1. Identification of Perinatal HIV Exposure	337
3.2. HIV Diagnosis in Infants	338
3.3. Immunological Monitoring in Children	338
3.4. Monitoring HIV RNA in Children	339
3.5. Initiation of Antiretroviral Therapy	340
3.6. Choice of Initial Antiretroviral Therapy	341
3.7. Changes in Antiretroviral Therapy	341
3.8. Duration of Therapy	342
3.9. Salvage Antiretroviral Therapy	343
Appendix	344
References	354
Index	357